MEDX - ETF AI Analysis
Top Page
Horizon Kinetics Medical ETF (MEDX)
Rating:65Neutral
Price Target:―
Positive Factors
Established Healthcare Leaders
The ETF’s largest positions include well-known, financially solid drug companies, which can provide stability within the portfolio.
Focused Healthcare Exposure
With most assets in the health care sector, the fund offers targeted exposure for investors who want to concentrate on medical and pharmaceutical companies.
Mix of Defensive and Growth Names
The portfolio blends large, steady pharmaceutical firms with more growth-oriented biotech names, offering a balance of potential resilience and upside.
Negative Factors
High Sector Concentration
Because the ETF is heavily invested in health care, it is more vulnerable if this single sector faces regulatory or pricing pressures.
Weak Recent Overall Performance
The fund’s returns over the year to date and recent three-month period have been negative, indicating it has been lagging the broader market recently.
Expensive for an ETF
The relatively high expense ratio means more of the fund’s returns are eaten up by fees compared with many lower-cost ETFs.
MEDX vs. SPDR S&P 500 ETF (SPY)
AUM17.91M
RegionGlobal
Expense Ratio0.85%
Beta0.57
IssuerHorizon Kinetics
Inception DateJan 30, 2023
Dividend Yield1.22%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume592
30 Day Avg. Volume1,876
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
41.87Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDX Summary
The Horizon Kinetics Medical ETF (MEDX) is a health care fund that does not track a specific index but focuses on medical companies of many types, including drug makers, biotech firms, medical device makers, and health care providers. It holds well-known names like Eli Lilly and Johnson & Johnson. Someone might invest in MEDX to seek long-term growth from medical innovation and an aging population, while getting diversification across many health care businesses. A key risk is that it is heavily concentrated in the health care sector, so its price can rise or fall sharply with changes in that industry.
How much will it cost me?The Horizon Kinetics Medical ETF (MEDX) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care investments that require more research and expertise.
What would affect this ETF?The Horizon Kinetics Medical ETF (MEDX) could benefit from ongoing advancements in medical research, an aging global population driving demand for health care, and increased health awareness globally. However, challenges such as regulatory changes, patent expirations for major pharmaceutical companies, or economic downturns impacting health care spending could negatively affect its performance. With top holdings like Eli Lilly and AbbVie, the ETF's success is closely tied to the innovation and market conditions within the health care sector.
MEDX Top 10 Holdings
MEDX is a pure health care play, and its story starts with Eli Lilly at the top: despite its heavyweight status, the stock has been losing steam this year, acting more like a brake than an engine. AbbVie and Ionis are also lagging, adding some drag to returns. Offsetting that, steady-to-rising names like Novartis, AstraZeneca, and Bristol-Myers are doing more of the heavy lifting, with Alkermes emerging as a quiet standout. With a global mix of big pharma and biotech, the fund is concentrated in drugmakers rather than devices or providers.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 16.84% | $2.98M | $959.51B | 45.64% | 72 Outperform | |
| AbbVie | 8.07% | $1.43M | $375.09B | 16.78% | 66 Neutral | |
| Novartis | 7.22% | $1.28M | $274.97B | 33.40% | 80 Outperform | |
| Johnson & Johnson | 5.51% | $974.51K | $552.02B | 50.26% | 78 Outperform | |
| AstraZeneca | 5.41% | $955.86K | $290.45B | 32.96% | 80 Outperform | |
| Ionis Pharmaceuticals | 4.87% | $861.44K | $12.40B | 124.06% | 61 Neutral | |
| Bristol-Myers Squibb | 4.83% | $854.42K | $119.54B | 26.62% | 78 Outperform | |
| Alkermes | 4.23% | $748.38K | $6.16B | 22.96% | 80 Outperform | |
| Amgen | 4.03% | $712.24K | $178.95B | 24.10% | 77 Outperform | |
| Merck & Company | 3.87% | $684.82K | $279.09B | 46.79% | 80 Outperform |
MEDX Technical Analysis
Positive
―
Price Trends
32.81
Positive
33.43
Positive
32.04
Positive
Market Momentum
0.05
Negative
57.70
Neutral
68.92
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MEDX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.62, equal to the 50-day MA of 32.81, and equal to the 200-day MA of 32.04, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 57.70 is Neutral, neither overbought nor oversold. The STOCH value of 68.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MEDX.
MEDX Peer Comparison
Comparison Results
Performance Comparison
MEDX
Horizon Kinetics Medical ETF
33.46
8.05
31.68%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents